AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca lynparza (olaparib) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables
Latest, FY2025
3,279
Period ended Dec 31, 2025
Change on a year earlier
+6.7%
3,072 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lynparza (olaparib) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,279 | +6.7% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 3,072 | +9.3% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 2,811 | +6.6% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 2,638 | +12.4% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 2,348 | +32.2% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 1,776 | +48.2% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 1,198 | +85.2% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 647 | +117.8% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 297 | +36.2% | Form 20-F (filed 2019-03-05) ↗ |
| FY2016 | Dec 31, 2016 | 218 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up lynparza (olaparib) — worldwide product sales ($m)
- Lynparza (olaparib) — Worldwide YoY actual (%)7.0% · FY2025
- Lynparza (olaparib) — Worldwide YoY CER (%)6.0% · FY2025
- Lynparza (olaparib) — US product sales ($M)1,434 · FY2025
- Lynparza (olaparib) — Emerging Markets product sales ($M)669 · FY2025
- Lynparza (olaparib) — Europe product sales ($M)914 · FY2025
- Lynparza (olaparib) — Established RoW product sales ($M)262 · FY2025
Cite this data
StockData. (2026). AstraZeneca Lynparza (olaparib) — Worldwide product sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_lynparza_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.